Pharmaceutical - Peregrine Pharmaceuticals

Filter

Current filters:

Peregrine Pharmaceuticals

Popular Filters

DCVax-L vaccine launch to boost glioblastoma market to $626 million by 2020

DCVax-L vaccine launch to boost glioblastoma market to $626 million by 2020

12-06-2014

The glioblastoma multiforme (GBM) treatment market is forecast to expand rapidly from a value of $301…

Celldex TherapeuticsCotaraDCVaxMarkets & MarketingNorthwest BiotherapeuticsOncologyPeregrine PharmaceuticalsPharmaceuticalResearchrindopepimut

Rapid growth forecast for glioblastoma multiforme therapeutics market

Rapid growth forecast for glioblastoma multiforme therapeutics market

06-06-2014

According to a new report, growth in the glioblastoma multiforme (GBM) therapeutics market in major developed…

Celldex TherapeuticsCotaraMarkets & MarketingNorthwest BiotherapeuticsPeregrine PharmaceuticalsPharmaceuticalrindopepimut

US FDA grants Peregrine Fast Track designation for bavituximab in NSCLC

US FDA grants Peregrine Fast Track designation for bavituximab in NSCLC

06-01-2014

US drugmaker Peregrine Pharmaceuticals (Nasdaq: PPHM) has received Fast Track designation from the US…

bavituximabOncologyPeregrine PharmaceuticalsPharmaceuticalRegulationUSA

Peregrine Pharma presents strong results from Ph II bavituximab trial

14-02-2013

Shares of US drugmaker Peregrine Pharmaceuticals (Nasdaq: PPHM) leapt 16% to $2.45, when it announced…

bavituximabBiotechnologyOncologyPeregrine PharmaceuticalsPharmaceuticalResearch

Peregrine Pharma plummets after revealing "discrepancies" in one bavituximab trial

25-09-2012

Shares of US drugmaker Peregrine Pharmaceuticals (Nasdaq: PPHM) went into free-fall in pre-market trading…

bavituximabBiotechnologyOncologyPeregrine PharmaceuticalsPharmaceuticalResearch

Peregrine leaps 56% as bavituximab shown to double NSCLC patient survival

10-09-2012

Shares of US biotech firm Peregrine Pharmaceuticals (Nasdaq: PPHM) rocketed 56.4% to $4.80 last Friday,…

bavituximabBiotechnologyOncologyPeregrine PharmaceuticalsPharmaceuticalResearch

Back to top